Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors

Pretreatment neutrophil to lymphocyte ratio as prognostic factor in metastatic breast cancer treated with cyclin dependent kinase 4/6 inhibitors

BackgroundCyclin dependent kinase inhibitors (CdK4/6i) changed the course of hormone receptor positive (HR+) HER2 negative (HER2-) metastatic breast cancer (mBC). To date, no factors have been shown to predict response to CdK4/6i. Neutrophil-to-lymphocyte ratio (NLR), an indicator of the host system...

Full description

Bibliographic Details
Main Authors: Pauline Rottier, George Emile, Alison Johnson, Christelle Levy, Djelila Allouache, Ioana Hrab, Carine Segura, Adeline Morel, Maud Villemin, Coraline Dubot-Poitelon, Louis Boismoreau, François Cherifi, Justine Lequesne, Angélique Da Silva
Format: Article
Language:English
Published: Frontiers Media S.A. 2023-01-01
Series:Frontiers in Oncology
Subjects:
metastatic breast cancer
NLR
cyclin dependent kinase inhibitor
prognostic factor
hormone dependent cancer
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.1105587/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.1105587/full

Similar Items